Parabilis Medicines Inc.
PBLS | NASDAQ
$28.32
-$0.38 (-1.32%)
At close: Oct 30, 2026, 4:00 PM ET
$28.64
+$0.32 (+1.13%)
Pre-market:
Nov 2, 2026, 5:36 AM ET
Company Profile
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Key Executives
| Name | Position |
|---|---|
| Mathai Mammen | CEO, President, Treasurer & Chairman |
| Kristen Stants | Chief People Officer |
| Thomas Rodolpho Kotarakos | Chief Financial Officer |
| Huei-in | Chief Business & Strategy Officer |
| John McGee | Scientific Co-Founder, Executive Vice President & Head of Platform |
| Jonathan Hurov | Executive Vice President of Discovery Biology |
| Marie Nguyen | Senior VP & Head of Clinical Development |
| Markus Haeberlein | Executive Vice President of Discovery Science |
| Mohammed Fawzi Benzaghou | Chief Medical Officer |
| Rohin Mhatre | Chief Technical Operations Officer |
| Teresa L. Jurgensen | Executive VP, Secretary & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 15, 2026 | 8-K | Current Report |
| Sep 02, 2026 | 8-K | Current Report |
| Aug 25, 2026 | 4 | Filing |
| Aug 25, 2026 | 3 | Filing |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 06, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 22, 2026 | 4 | Filing |
Parabilis Medicines Inc.
| Country | United States |
| IPO Date | Jun 10, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
| CEO | Mathai Mammen |
Contact Details
30 Acorn Park Dr Cambridge,
Massachusetts 02140 United States
Stock Details
| Ticker Symbol | PBLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001657677 |
| CUSIP Number | 698955101 |
| ISIN Number | US6989551014 |
| SIC Code | 2834 |
Recent News
- 6 days ago / seekingalpha.comParabilis Medicines: Bullish On Zolucatetide's Broad Oncology Potential
- 6 days ago / seekingalpha.comParabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript
- 9 days ago / marketbeat.comParabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
- 9 days ago / globenewswire.comParabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
- 13 days ago / seekingalpha.comParabilis: $1B+ Rare-Disease Foundation Leaves The Big Oncology Pipeline For Free
- 14 days ago / globenewswire.comParabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
- 19 days ago / globenewswire.comParabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
- 2 months ago / globenewswire.comParabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.
- 3 months ago / seekingalpha.comParabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform
- 3 months ago / globenewswire.comParabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Add to Watchlist
Select watchlists to add or remove PBLS